Investment Rating - The report maintains an "Outperform" rating for the company [2]. Core Insights - The company's performance in 2025 was impacted by a challenging consumption environment, resulting in a revenue decline of 18.9% to RMB 2.45 billion and a net profit decrease of 34.1% to RMB 1.29 billion [5][15]. - The acquisition of REGEN Biotech has positioned the company for future growth, with new products like AestheFill and PowerFill expected to contribute to revenue [7][19]. - The company is entering a new growth phase with the approval of Type A botulinum toxin, which is anticipated to enhance its product offerings [19]. Financial Performance Summary - Revenue for 2025 was RMB 2,453 million, down 18.9% from the previous year, with a net profit of RMB 1,291 million, reflecting a 34.1% decline [5][15]. - Quarterly revenue for 2025 showed slight recovery in Q4, with a 3.9% increase from Q3, although it was still down 9.6% year-on-year [5][16]. - The gross profit margin for 2025 was 92.7%, a decrease of 1.9 percentage points compared to the previous year [5][15]. Product Performance Summary - Revenue from solution-type products was RMB 1.26 billion, down 27.5%, while gel-type products generated RMB 890 million, down 26.8% [6][17]. - The newly acquired freeze-dried powder products generated RMB 210 million, indicating a new growth driver for the company [6][17]. - Other revenue, including cosmetics, increased by 36.7% to RMB 90 million, showcasing some resilience in the product mix [6][17]. Expense Analysis - The company's expense ratios increased significantly, with sales expense ratio at 15.8% (+6.7 percentage points), administrative expense ratio at 7.4% (+3.3 percentage points), and R&D expense ratio at 14.7% (+4.7 percentage points) [6][18]. - The increase in expenses is attributed to the dilution effect from declining revenue, costs associated with the REGEN acquisition, and ongoing R&D investments [6][18]. Earnings Forecast and Valuation - Revenue is expected to grow to RMB 2.70 billion in 2026 and RMB 2.92 billion in 2027, representing year-on-year growth of 10.1% and 8.2%, respectively [9][20]. - Net profit is projected to reach RMB 1.39 billion in 2026 and RMB 1.47 billion in 2027, with growth rates of 7.9% and 5.5% [9][20]. - The target price for the stock is set at RMB 160.6, based on a P/E ratio of 35x for 2026, reflecting a downgrade from previous estimates [9][20].

Summary of Key Points from the Medical Aesthetic Industry Conference Call Industry Overview - The medical aesthetic industry has shown fluctuations in revenue at offline terminal institutions, with January 2026 experiencing an 11% year-on-year growth, while February saw a 4% decline due to the Spring Festival impact. Overall growth for the first two months is approximately 6% with a 10% increase in customer traffic, although the average transaction value continues to decline [1][4]. Core Insights and Arguments - **Shift Towards Light Medical Aesthetics**: The increasing proportion of light medical aesthetics has led to a decrease in average transaction prices. Institutions are encouraged to introduce high-margin products or equipment to maintain profit margins [1][5]. - **Non-Surgical Procedures Dominance**: Non-surgical procedures now account for 66%-70% of total services, with light-based skin treatments stable at 40%-45% and injection procedures on the rise. The demand for light-based skin equipment remains high, particularly for anti-aging treatments, although average transaction prices may continue to decline [1][8][9]. - **Injection Product Line Growth**: The injection product line is expected to see significant growth, with new products like hyaluronic acid, novel botulinum toxins, and recombinant collagen being introduced. Institutions are actively pursuing OEM custom branding to reduce costs and improve profit margins [1][10][11]. - **Hyaluronic Acid Market Trends**: High-end imported brands remain popular, but OEM custom-branded hyaluronic acid is becoming a key focus, showing remarkable growth rates of 100% to 200%. Traditional brands are experiencing slower growth, while differentiated new brands are performing well [1][12]. - **Recombinant Collagen Market Outlook**: The recombinant collagen market has shown significant growth, with expectations for continued strong performance in 2026. New entrants may pose challenges to established players, but new product launches are likely to expand market share [1][13]. - **Botulinum Toxin and Youthful Injection Products**: The botulinum toxin product line has maintained stable growth, with new approvals expected to drive sales. The youthful injection market is stabilizing but may see development through new technologies and differentiated products [2][14]. Regulatory and Market Dynamics - **Increased Regulation**: Stricter regulations in the medical aesthetic industry are promoting compliance and supporting the approval of new product lines. The introduction of VAT on consumer medical services adds pressure, but reasonable deductions can alleviate some burdens [1][6]. - **Market Competition**: The competition is expected to intensify in 2026, with a forecasted revenue growth of 8% to 10%. The rise of light medical aesthetics is attracting younger consumers, while first-tier cities are seeing slower growth compared to second and third-tier cities [1][7]. Additional Important Insights - **Emerging Product Categories**: New categories such as recombinant collagen and youthful water light products are anticipated to perform well in 2026. PDRN (polydeoxyribonucleotide) products, although not yet approved, are gaining attention due to strong demand [1][18]. - **PDRN Market Potential**: Companies like Lepu Medical are progressing rapidly in the PDRN field, with the potential for a market size of 1 billion to 2 billion once the first registration certificate is issued [1][19].

Core Viewpoint - The National Health Commission emphasizes that "light medical beauty" services must be conducted in qualified medical institutions by professional medical personnel, highlighting the risks associated with unregulated practices in the industry [1][2]. Group 1: Industry Overview - The medical beauty industry has seen rapid growth, particularly in "light medical beauty" services such as laser treatments and drug injections, attracting many consumers [2]. - There is a rising concern over unqualified businesses exploiting "appearance anxiety" and concealing the risks associated with medical beauty procedures [2]. Group 2: Regulatory Concerns - The National Health Commission warns against "light medical beauty crash courses" that trivialize medical practices, often leading to illegal medical activities and consumer deception [2]. - Illegal practices include unauthorized training, improper use of medical beauty products, and issuing fake training certificates, which pose significant health risks to the public [2].

Policy Developments - The National Health Commission of China has prohibited beauty institutions, hair salons, and nail salons from conducting "light medical beauty" projects due to rising concerns over safety and qualifications in the medical beauty industry [2] Industry Developments - A new international trading platform for medical devices and instruments has been launched in Tianjin, aimed at facilitating "global buying and selling" of medical equipment, enhancing cross-border cooperation, and reducing international trade costs [3] - The Chinese Center for Disease Control and Prevention reported a general decline in acute respiratory infectious disease epidemics, with flu levels remaining low across the country [14] Drug and Device Approvals - Fosun Pharma announced that its subsidiary Shanghai Chaohui Pharmaceutical's application for the registration of Bupivacaine Hydrochloride Gel has been accepted by the National Medical Products Administration [5] - GlaxoSmithKline's RSV vaccine Arexvy has had its registration application accepted in China, with expectations for approval by 2027 [6] Financial Reports - AstraZeneca reported a total global revenue of $58.739 billion for 2025, marking an 8% year-on-year increase, with revenue from China reaching $6.654 billion, a 4% increase [8] Capital Market Activities - Beijing Supervision Biotechnology Co., Ltd. completed a B+ round financing exceeding 100 million yuan, with investments from multiple funds aimed at advancing its technology in clinical and brain disease intervention [10] - Hangzhou Tangji Medical Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange [11] Industry Events - The first round of national centralized procurement for 316 commonly used drugs has been conducted, involving over 5,100 medical institutions and 1,091 domestic and foreign companies, with results expected to be implemented by March 2026 [13] - Samsung Medical's subsidiary has been recommended as a candidate for a project worth approximately 321 million yuan with Southern Power Grid [15]

Core Viewpoint - The National Health Commission has clarified that "light medical beauty" is considered a medical practice, prohibiting beauty institutions from conducting illegal operations. The rise of "light medical beauty" has led to frequent injury incidents due to unqualified personnel performing procedures in non-medical settings, prompting the public to choose legitimate medical institutions and report any suspicious activities [1][2]. Group 1: Definition and Regulation - "Light medical beauty" is defined as non-surgical medical beauty projects utilizing injection, phototherapy, and biotechnology, which must be conducted in licensed medical institutions by qualified medical professionals [3]. - Beauty salons and similar establishments are only permitted to offer non-invasive services and are strictly prohibited from performing any procedures that involve skin penetration or the use of medical devices [3]. Group 2: Industry Risks and Consumer Protection - The proliferation of "quick training courses" for medical beauty procedures is concerning, as they often lead to illegal medical practices and the distribution of counterfeit products [4]. - Consumers are advised to verify the legitimacy of medical beauty institutions by checking for a valid medical institution license, ensuring that practitioners possess the necessary medical qualifications, and confirming that products used are approved by the national drug regulatory authority [4].

Core Viewpoint - The rapid development of the medical beauty industry, particularly "light medical beauty" practices, has raised concerns about health risks due to unqualified practitioners and illegal training programs [1][3] Group 1: Industry Concerns - "Light medical beauty" refers to non-surgical medical beauty projects conducted through injections, phototherapy, and biotechnology, which must be performed in qualified medical institutions by professional medical personnel [3] - There is a growing trend of unqualified businesses exploiting "appearance anxiety" to promote illegal practices, including unauthorized "light medical beauty crash courses" that lead to health risks for the public [1][3] Group 2: Regulatory Emphasis - Non-medical beauty institutions, such as beauty salons and nail shops, are strictly prohibited from offering "light medical beauty" services, emphasizing the importance of prioritizing health and safety over cost [3] - The promotion of "light medical beauty crash courses" often involves misleading marketing tactics that obscure qualifications and simplify techniques, leading to illegal medical practices and the issuance of fake training certificates [3]

Core Viewpoint - The National Health Commission of China has raised concerns about "light medical beauty crash courses," highlighting that these programs often involve various illegal activities and mislead consumers through vague qualifications and simplified techniques [1][2] Group 1: Industry Concerns - The rapid growth of the medical beauty industry, particularly in non-surgical procedures like injections and laser treatments, has attracted many consumers, but it has also led to the emergence of unscrupulous businesses exploiting "appearance anxiety" [1] - Illegal activities associated with "light medical beauty crash courses" include unauthorized medical practices, false training, illegal use of medical beauty drugs and devices, and issuing fake training certificates [2] Group 2: Public Advisory - The National Health Commission advises the public to be cautious and not to trust marketing phrases like "three-day crash course in injections" or "zero foundation, learn with confidence," as these can lead to significant health risks [1][2] - It is emphasized that "light medical beauty" procedures must be conducted in qualified medical institutions by licensed medical professionals, and non-medical establishments like beauty salons and nail shops are prohibited from offering these services [1]

Macro Dynamics - Five departments, including the Ministry of Industry and Information Technology, are accelerating the development of guidelines for the utilization and technological innovation of low-altitude economic radio frequency resources to support low-altitude infrastructure development [2] Health and Safety - The National Health Commission has warned against "light medical beauty" projects being conducted by non-medical institutions, emphasizing that such procedures must be performed in qualified medical facilities by licensed professionals to mitigate health risks [3] Market Data - The State Administration for Market Regulation conducted a special inspection of food safety ahead of the Spring Festival, testing 67,000 batches with a compliance rate of 98.38%, indicating overall good food safety conditions [4] - The National Healthcare Security Administration announced the results of the first to eighth batches of national drug procurement, involving 316 commonly used drugs and 1,020 enterprises with 4,163 products qualifying for selection [5] Financial Institutions - China Bank has increased its registered capital from approximately 294.4 billion RMB to about 322.2 billion RMB, marking an increase of approximately 9.5% [6] Market Performance - On February 10, the A-share market showed mixed results, with the Shanghai Composite Index rising by 0.13% and the ChiNext Index falling by 0.37%, while the total trading volume was approximately 2,105.5 billion RMB, a decrease of about 143.9 billion RMB from the previous trading day [7] - The Hong Kong stock market closed with the Hang Seng Index up by 0.58% and the Hang Seng Tech Index up by 0.62%, driven by significant gains in the pharmaceutical and media sectors [8] Company Dynamics - *ST Lifan announced that its stock will resume trading on February 11 after completing an investigation into stock price fluctuations, noting that the company's fundamentals have not changed significantly [9] - Semiconductor Manufacturing International Corporation reported a net profit of 1.223 billion RMB for Q4 2025, a year-on-year increase of 23.2%, with total revenue of 17.813 billion RMB, up 11.9% [11] - WeChat has launched a "national subsidy" interest service for credit card bill installment repayments, with seven banks participating in the initial rollout [10] - Chow Tai Fook confirmed that it will raise prices for gold products after the Spring Festival, although the timing and extent of the increase have yet to be determined [13] - Sam's Club, Hema, and Dingdong Maicai announced adjustments to service arrangements and delivery fees during the Spring Festival period [15]

Core Viewpoint - The National Health Commission has issued a clear warning regarding the "light medical beauty" industry, highlighting the risks associated with unqualified practitioners and illegal training programs that pose serious health threats to consumers [1][3][4]. Group 1: Industry Overview - "Light medical beauty" refers to non-surgical or minimally invasive medical beauty procedures aimed at achieving skin care, anti-aging, and body shaping effects, characterized by short recovery times and relatively low risks [3][4]. - The market for light medical beauty is rapidly growing, with an expected user base of 31.05 million in China by 2025. Among consumers, 46.02% prioritize "relatively controllable risks" when considering medical beauty projects, and light medical beauty accounts for 74.45% of the procedures they have undergone [3]. Group 2: Regulatory Concerns - The National Health Commission emphasizes that light medical beauty is a medical practice that must be conducted by licensed medical personnel in accredited medical institutions. It is strictly prohibited for lifestyle beauty salons, hair salons, and nail salons to offer such services [4]. - Illegal practices, such as "light medical beauty crash courses," mislead consumers by blurring the lines of qualifications and simplifying techniques, often leading to illegal medical practices, counterfeit training certificates, and the use of unapproved medical products [4]. Group 3: Public Health Recommendations - Experts at the press conference provided health protection advice related to flu prevention, spring health maintenance, and weight management, addressing public health concerns during the seasonal transition [6][7]. - Current flu activity is at a low level, with a downward trend in acute respiratory infections. The main circulating strain is the H3N2 subtype of the influenza virus [6].

Core Viewpoint - The National Health Commission of China has raised concerns about the "light medical beauty" industry, highlighting the risks associated with unqualified practitioners and illegal training programs [1] Industry Summary - The "light medical beauty" sector has rapidly developed, primarily involving laser and injectable treatments, attracting many consumers [1] - Unethical businesses exploit "appearance anxiety," concealing the risks of medical beauty procedures and conducting illegal "crash courses" for training [1] - Incidents of injury and disability have occurred due to unqualified individuals performing medical beauty procedures [1] Regulatory Emphasis - "Light medical beauty" refers to non-surgical medical beauty procedures conducted by qualified medical personnel in accredited medical institutions [1] - Non-medical establishments such as beauty salons, hairdressing shops, and nail salons are prohibited from offering "light medical beauty" services [1] Illegal Practices - "Crash courses" in medical beauty often misrepresent medical practices as lifestyle services, misleading consumers through vague qualifications and simplified techniques [1] - Common illegal activities include practicing medicine without a license, fraudulent training, illegal use of medical beauty products and devices, and issuing fake training certificates [1] - The National Health Commission advises the public to be wary of marketing phrases like "three-day crash course" and "zero foundation beginners welcome" [1]